Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 16/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12664401 | 0.83 | FYN (0.55) | FYNKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL23535613 | 0.82 | AURKA (0.73) | FYNRXFP1 | |
| SCHEMBL25066869 | 0.81 | FYN (0.66) | FYN | |
| SCHEMBL10391047 | 0.80 | POLB (0.76) | FYNKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL23535621 | 0.79 | FYN (0.80) | FYN | |
| SCHEMBL13498808 | 0.78 | MAP3K5 (0.55) | FYNKDM4E | |
| SCHEMBL18613782 | 0.78 | FYN (1.00) | FYN | |
| SCHEMBL3476408 | 0.77 | SMN1; SMN2 (0.73) | FYNKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3091846 | 0.77 | PIK3CG (0.80) | — | |
| SCHEMBL16331230 | 0.77 | FYN (1.00) | FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120025336-A | LIN28 inhibitors and methods of use thereof | 加利福尼亚大学董事会 | 2025-05-23 | — | — | CN | disclosed |
| CN-115087657-B | LIN28 inhibitors and methods of use thereof | 加利福尼亚大学董事会 | 2025-01-21 | — | — | CN | disclosed |
| US-20230059009-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-02-23 | — | — | US | disclosed |
| US-20230059009-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-02-23 | — | — | US | disclosed |
| EP-4077332-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021126779-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126779-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230059009-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | LIN28A, DDX21, BMI1 | FYN 3592/4885KDM4E 219/4885ALDH1A1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.